Blanco-Aparicio, Marina
Domínguez-Ortega, Javier
Cisneros, Carolina
Colás, Carlos
Casas, Francisco
del Cuvillo, Alfonso
Alobid, Isam
Quirce, Santiago
Mullol, Joaquim http://orcid.org/0000-0003-3463-5007
Funding for this research was provided by:
Sanofi España (Sanofi España)
Article History
Received: 8 September 2022
Accepted: 27 February 2023
First Online: 23 April 2023
Declarations
:
: Not applicable.
: Not applicable.
: MBA has received honoraria for lectures, courses, participation in monographs and standards, or scientific advice from AstraZeneca, Sanofi, Esteve, GSK, Menarini, Novartis, Chiesi, and TEVA. JDO has received funding for research and/or honoraria for consultancy and conferences from AstraZeneca, Chiesi, GSK, Bial, Novartis, Sanofi, and TEVA; and speaker fees from ALK, LETI Pharma, and Mundipharma. CCis has received financial aid from AstraZeneca, Chiesi, Novartis, Mundipharma, GSK, Pfizer, Menarini, and Sanofi for advisory services, papers, research studies, attendance at congresses or training courses. CCol has received honoraria for lectures, courses, participation in monographs and standards or scientific advice from AstraZeneca, Sanofi, GSK, Novartis, Viatris and Chiesi. FCM has received honoraria for lectures, courses, participation in monographs and standards or scientific advice from AstraZeneca, Chiesi, GSK, Novartis, Sanofi, and TEVA. AC reports grants and personal fees from MYLAN, FAES Pharma, Novartis, Allakos, and Sanofi; personal fees from ALK, GSK, MSD, AstraZeneca, and TEVA, outside the submitted work. IA has received honoraria for consultancy and conferences from Viatris, Sanofi, GSK, MSD, Menarini, GAES, Aural, and Novartis. SQ has received honoraria for consultancy and conferences from AstraZeneca, GSK and Sanofi, and speaker fees from Chiesi, Mundipharma, Novartis, and TEVA. JM is a member of national or international advisory boards and has received speaker fees or funding for clinical trials and research projects from Allakos, AstraZeneca, GSK, Menarini, Mitsubishi-Tanabe, MSD, Mylan-MEDA Pharma (Viatris), Novartis, Regeneron Pharmaceuticals, Sanofi, UCB Pharma, and Uriach Group.